P eripheral chemoreceptors located in the carotid sinus sense changes in arterial CO 2 and O 2 and communicate this infor mation to cardiorespiratory centers to regulate breathing and sympathetic outflow to ensure adequate ventilation-perfusion matching in tissues. There is strong evidence that overactiva tion of the peripheral chemoreflex by repeated bouts of hypoxia contributes to hypertension and cardiovascular mortality associ ated with obstructive sleep apnea.
P eripheral chemoreceptors located in the carotid sinus sense changes in arterial CO 2 and O 2 and communicate this infor mation to cardiorespiratory centers to regulate breathing and sympathetic outflow to ensure adequate ventilation-perfusion matching in tissues. There is strong evidence that overactiva tion of the peripheral chemoreflex by repeated bouts of hypoxia contributes to hypertension and cardiovascular mortality associ ated with obstructive sleep apnea. [1] [2] [3] [4] However, despite intense investigation, molecular mechanisms linking peripheral chemo receptor drive to hypertension remain poorly understood.
It is well known that peripheral chemoreceptor afferents first synapse in the caudal portion of the nucleus tractus solitarii (cNTS) 5, 6 before relaying this information primarily to the rostral ventrolateral medulla (RVLM), including at the level of the retrotrapezoid nucleus (RTN). [7] [8] [9] This brain stem region contains ≥2 functionally discrete but anatomically overlapping populations of neurons: CO 2 /H + sensitive RTN neurons that seem to function as respiratory chemoreceptors 10 and C1 and nonC1 cells that control sympathetic vasomotor tone and arte rial pressure. [11] [12] [13] [14] Evidence suggests that both RTN chemore ceptors 9 and C1 cells 15 receive peripheral chemoreceptor drive. The transmitter basis for this drive is thought to depend largely on glutamate because NTS terminals in this region are immu noreactive for vesicular glutamate transporter 2 (VGLUT2, a marker of glutamatergic cells) 16, 17 , and bilateral injections of kynurenic acid (glutamate receptor blocker) blunted peripheral chemoreceptor-mediated activation of breathing and blood pressure. 9, 18 However, purinergic signaling has also been impli cated in the peripheral chemoreflex, [19] [20] [21] [22] including at the level of the RVLM. 23 For example, chemosensitive RTN neurons 24, 25 and presympathetic RVLM neurons 26 are activated by puriner gic agonists, application of purinergic agonists into the RVLM increased breathing 27, 28 and blood pressure 29, 30 in anesthetized rats, and inhibition of P2 receptors in the nearby Bötzinger and preBözinger complex blunted the respiratory response evoked by peripheral chemoreceptor activation in awake rats. 23 These results suggest that purinergic signaling contributes to the peripheral chemoreflex mechanism. However, the identity of P2 receptors regulating the peripheral chemoreflex at this level of the brain stem is unknown.
We have recently determined that P2Y1 receptors are expressed in the RVLM. 31 Although these receptors do not influence cardiorespiratory responses to hypercapnia, appli cation of a P2Y1 receptor agonist into this region mimicked effects of peripheral chemoreceptor activation by increasing breathing and blood pressure. 31 Therefore, we hypothesize that P2Y1 receptors are differentially expressed by C1 neurons and function as key determinants of peripheral chemorecep tor drive through this region. Consistent with this possibil ity, we find that inhibition of P2Y1 receptors in the RVLM decreased breathing, sympathetic nerve activity (SNA), and blood pressure responses to cyanideinduced activation of peripheral chemoreceptors in anesthetized rats. Furthermore, NTS terminals at this level of the RVLM are immunoreactive for vesicular nucleotide transporter (VNUT). To establish that P2Y1 receptors are expressed by C1 cells, we determine in the brain slice preparation that cells responsive to specific P2Y1 receptor agonist (MRS2365) are immunoreactive for tyrosine hydroxylase (TH, a marker of C1 cells), and we determine in vivo that C1lesioned animals do not respond to RVLM injec tion of MRS2365. We find that P2Y1 receptors are key deter minants of peripheral chemoreceptor regulation of breathing, SNA, and blood pressure.
Methods
All procedures were performed in accordance with National Institutes of Health and the University of Connecticut and University São Paulo Animal Care and Use Guidelines. An expanded Methods section is available in the onlineonly Data Supplement.
Results
This study consists of both in vivo and in vitro experiments. First, to determine whether purinergic signaling in the RVLM contributes to peripheral chemoreceptor regulation of breath ing, sympathetic activity, or blood pressure, we measured these parameters during cyanideinduced activation of periph eral chemoreceptors after bilateral RVLM injections of saline, a nonspecific P2 receptor blocker (pyridoxalphosphate6 azophenyl2′,4′disulfonic acid [PPADS]) or a specific P2Y1 receptor blocker (MRS2179). 32 To further support the pos sibility that purinergic signaling contributes to peripheral chemoreceptor drive, we determine the extent to which NTS terminals in the RVLM are immunoreactive for VNUT and VGLUT2. Although our focus is on the peripheral chemore flex, we also tested the possibility that purinergic signaling via P2Y1 receptors contributes to other reflexes mediated by C1 cells, including the somatosympathetic reflex and the baroreflex. Second, to determine which neurons express P2Y1 receptors, we used slicepatch recording techniques to measure neuronal responses to focal application of a specific P2Y1 receptor agonist (MRS2365). 33 As in previous stud ies, 10 To determine whether purinergic signaling contributes to peripheral chemoreceptor transduction in the RVLM, we measured breathing, sympathetic outflow, and blood pressure responses to peripheral chemoreceptor activation after bilat eral RVLM injections of saline or a purinergic receptor antag onist ( Figure 1A ). 34 The injection center was 250 µm below the facial motor nucleus and 200 µm rostral to the caudal end of this nucleus ( Figure 1B) . 10, 35 Bilateral injections of PPADS (100 µmol/L, 50 nL) into the RVLM did not change baseline mean arterial pressure (MAP; 119±5 mm Hg compared with saline 121±6 mm Hg), splanchnic SNA (sSNA; 101±11% of control), or phrenic nerve activity (PNA) activity (97±4% of control value). However, PPADS treatment strongly inhibited cardiorespiratory responses to peripheral chemoreceptor acti vation. For example, PPADS attenuated the increase in sSNA (78±10% versus saline 211±13%; P=0.015; n=7), MAP (12±3 mm Hg versus saline 25±6 mm Hg; P=0.037), and PNA ampli tude (84±4% versus saline 121±14%; P=0.038) and frequency (45±7% versus saline 118±8%; P=0.026) elicited by cyanide ( Figure 1A, 1C-1F ).
Previous evidence showed that P2Y1 receptors are expressed in the RVLM. 31 However, P2Y1 receptors do not influence CO 2 responsiveness in vitro or in vivo, suggesting that these recep tors relay a purinergic signal disparate from CO 2 evoked ATP release, but still essential to autonomic regulation of cardiore spiratory homeostasis. To determine whether P2Y1 receptors are part of the peripheral chemoreceptor circuit, we repeated the experiments described above using the specific P2Y1 receptor antagonist (MRS2179) alone or in combination with a nonspecific ionotropic glutamate receptor antagonist (kyn urenic acid; Figure 2B ). As previously reported, 31 Figure 2A and 2C) and decreased the sympathoexcitatory response from 218±17% to 126±8% (P=0.028; Figure 2A and 2D). Similarly, MRS2179 also decreased peripheral chemoreceptor activation of PNA amplitude and frequency by 25±6% (P=0.037; Figure 2A and 2E) and 33±7% (P=0.032; Figure 2A and 2F), respectively. Consistent with previous evidence, 36 bilateral RVLM injec tions of kynurenic acid decreased baseline PNA amplitude (59±5%) and increased PNA frequency (46±4%), but did not affect sSNA or MAP. Injections of kynurenic acid into the RVLM also blunted the peripheral chemoreceptor-mediated increase in breathing amplitude, SNA, and blood pressure ( Figure 2A, 2C-2F ). The effect of kynurenic acid on PNA frequency was reduced by MRS2179 (137±6 versus 169±4 breaths/min; Figure 2A and 2F). In addition, the combination of kynurenic acid and MRS2179 further decreased periph eral chemoreceptor-mediated changes in MAP (64% inhibi tion), sSNA (69% inhibition), and phrenic nerve discharge amplitude (68% inhibition) by more than either blocker alone ( Figure 2A, 2C-2E ). These results indicate that purinergic Injections located outside the RVLM region often reached the facial motor nucleus or dorsal to it (3 of 4), and 1 injec tion (1 of 4) was located in the parapyramidal region (data not shown). Bilateral injections of PPADS, MRS2179, or kynurenic acid into the facial motor nucleus or parapyramidal region did not change the cyanideinduced respiratory or pres sor responses in these animals (data not shown).
Purinergic Signaling in the RVLM Contributes to the Excitatory Somatosympathetic Reflex But Not the Inhibitory Baroreflex
To determine whether P2Y1 receptor-dependent modulation of C1 cells is specific to the peripheral chemoreflex, we also tested effects of MRS2179 on 2 other reflexes mediated by C1 cells: the somatosympathetic reflex which is thought to be mediated by glutamate in the RVLM 37 and the baroreflex which is inhibitory and largely mediated by gammaaminobu tyric acid in the RVLM. 38 The somatosympathetic reflex was represented by 2 characteristic excitatory peaks in the sSNA in response to intermittent sciatic nerve stimulation under baseline conditions (control) and after injections of saline or MRS2179 (100 µmol/L to 50 nL). As shown in Figure 3A , latencies of the peaks of sSNA (85±3 and 176±3 ms, respec tively; n=4) were not significantly altered by bilateral injec tion of MRS2179 (sSNA: 89±4 and 179±5 ms, respectively; P=0.145; n=5). However, bilateral RVLM injections of MRS2179 decreased the area under the curve of each sSNA peak by 25±4% (P=0.042) and 22±5% (P=0.044), respec tively ( Figure 3A and 3B).
The baroreflex was measured by raising arterial pressure with phenylephrine (5 μg/kg, IV) and lowering arterial pres sure with sodium nitroprusside (30 μg/kg, IV). A baroreflex curve relating MAP and SNA was constructed for each rat under control conditions and 10 minutes after bilateral injec tions of saline or MRS2179 (100 µmol/L to 50 nL; n=5). We found that the baroreflex operated around a compa rable MAP50 in all groups (MRS2179: 116±9 versus saline 118±6 mm Hg; P=0.46; Table) . Injections of MRS2179 into the RVLM did not change the range (135±11% versus saline 138±13%; P=0.37) and the gain (5.3±0.5 versus saline 5.4±1%; P=0.71) of the sympathetic baroreflex (Table) .
To confirm in vivo that MRS2179 is specific to P2Y1 recep tors and does not disrupt glutamatergic signaling, we test effects of MRS2179 on cardiorespiratory responses to RVLM injections of glutamate in urethaneanesthetized rats. Injection of MRS2179 (100 µmol/L to 50 nL; n=5) in the RVLM did not change the increase in MAP (23±4 mm Hg versus saline 27±2 mm Hg; P=0.064), sSNA (34±8% versus saline 33±9%; P=0.084), PNA amplitude (17±2% versus saline 18±4%; P=0.13), or PNA frequency (14±2% versus saline 16±4%; P=0.077) evoked by unilateral injection of glutamate (10 mmol/L to 50 nL) in the RVLM ( Figure S1 in the onlineonly Data Supplement).
Together, these results suggest that application of MRS2179 into the RVLM does not antagonize glutamate receptors. These results also suggest that purinergic signaling via P2Y1 receptors in the RVLM contributes to excitatory (ie, peripheral chemoreflex and the somatosympathetic reflex) but not inhibi tory baroreflex control of sympathetic activity. This study focuses on the peripheral chemoreflex because overactivation of this reflex is thought to contribute to hypertension associ ated with obstructive sleep apnea.
VNUT Is Expressed by NTS Neuronal Terminals in the RVLM
Our observation that P2Y1 receptors in the region of the RVLM contribute to the peripheral chemoreflex suggests that synapses activated in the RVLM during peripheral chemore ceptor stimulation release purinergic signaling molecules. To build on this possibility, we injected the anterograde tracer biotinylated dextran amine (BDA) into the cNTS ( Figure 4A and 4B) and subsequently performed immunohistochem istry to determine whether cNTS terminals in the RVLM express VNUT, the protein responsible for vesicular stor age and release of nucleotides. 39 Considering that purinergic Baroreflex analysis after bilateral injection of saline or MRS2179 (100 µmol/L to 50 nL) injection into RVLM. Curves relating splanchnic nerve activity (sSNA) and mean arterial pressure (MAP) were generated by lowering MAP with sodium nitroprusside (SNP, 30 μg/kg, IV) and increasing MAP with phenylephrine (Phe, 5 μg/ kg, IV). Baseline sSNA was set to 100%, and minimum sSNA was determined after intravenous injection of hexamethonium (30 mg/kg, IV). RVLM indicates rostral ventrolateral medulla.
by guest on April 19, 2017 http://hyper.ahajournals.org/ Downloaded from nucleotides are known to be coreleased with glutamate at cer tain central synapses 39 and cNTS projections to the RVLM are known to be glutamatergic, 9 we also assayed for VGLUT2 to determine whether glutamate and nucleotides are colocalized in the same terminals.
We focused our observations on the marginal layer of the ventrolateral medulla between Bregma −11.3 and Bregma −12.2 because this region contains chemosensitive 9, 10, 25, 31 neurons and C1 15, 17 cells, and it is known to receive a dense input from the cNTS. 9 BDAlabeled varicosities were assumed to be terminals (putative synapse). This possibil ity is supported by our evidence that the majority of BDA labeling was immunoreactive for VNUT and VGLUT2. Figure 4C -4F shows examples of this staining where ter minals from the cNTS (green) are immunoreactive for VGLUT2 (red) and VNUT (blue). A total of 126 terminals from 31 RVLM regions (n=4 rats) were counted, and 72 (57%) were positive for both VGLUT2 and VNUT, 25 (20%) were VGLUT2positive only, 8 (6%) were VNUTpositive only, and 21 (17%) lacked any discernible immunoreactivity ( Figure 4G ). Although it is not surprising to find numerous BDAlabeled terminals in which no other immunoreactivity could be detected, it should be noted that in the absence of a vesicular marker, at least some BDA labeling may reflect cut axons rather than terminals.
C1 Cells But Not RTN Chemoreceptors Express P2Y1 Receptors
To determine the cellular distribution of P2Y1 receptors in the region of the RVLM, we used the brain slice preparation to make cellattached recordings of action potential frequency in response to 15% CO 2 and focal application of MRS2365 (100 µmol/L). We found that the majority of RVLM neurons (62 of 78) could be differentiated based on responsiveness to either CO 2 /H + or MRS2365. Note that an increase of ≥0.5 Hz immediately after MRS2365 application was the cut off for a neuron to be considered MRS2365 sensitive. For example, 22 of 25 chemosensitive neurons (88%; ie, ≥1.5 Hz increase in firing rate during 15% CO 2 ) demonstrated no appreciable response to focal application of MRS2365 ( Figure 5A ). Conversely, 37 of 53 CO 2 /H + insensitive neu rons (≈70%) exhibited a robust firing rate response to focal application of MRS2365. Furthermore, responsiveness to MRS2365 was retained in synaptic block solution ( Figure 5D and 5E) and blunted by bath application of MRS2179, a spe cific P2Y1 receptor blocker 32 (3 µmol/L; Figure 5B and 5C). All MRS2365insensitive but CO 2 /H + sensitive neurons had baseline firing rates <1 Hz (data not shown), consistent with type 1 RTN chemosensitive neurons. 40 However, 3 CO 2 /H + sensitive neurons did respond to MRS2365, and each of these exhibited basal activity reminiscent of type II chemorecep tors (ie, ≥1 Hz), 40 suggesting that a small subset of chemo sensitive neurons may express P2Y1 receptors. Nevertheless, our results clearly show that the majority of P2Y1 recep tors are expressed by CO 2 /H + insensitive cells ( Figure 6A ). After recording, we gained wholecell access to fill a sub set of MRS2365senstive cells with biocytin (included in the pipette internal solution) for later determination of their immunohistochemical phenotype. We found that 9 of 18 MRS2365sensitive cells were THimmunoreactive, thus To further support the possibility that C1 cells preferentially express P2Y1 receptors, we tested MRS2365 responsiveness in C1lesioned animals. To preferentially destroy C1 cells, we made bilateral RVLM injections of saporin (SAP) (an immu notoxin) that was conjugated to an antibody for dopamine βhydroxylase (anti-DβHSAP; 4.2 ng/100 nL) as previously described. 15, 41 Two weeks after anti-DβHSAP injection, TH labeling was examined within the ventrolateral medulla to confirm specificity of the lesion to C1 cells. To confirm speci ficity of the C1 lesion, we also examined Phox2b immunore activity. Phox2b is a transcription factor strongly expressed by chemosensitive RTN neurons, but only weekly expressed by C1 cells. Therefore, we define C1 cells as TH positive and Phox2b negative (TH + /Phox2b − ). Animals treated with anti-DβHSAP showed an 86±4% reduction in the number of cells that were TH positive and Phox2b negative compared with salineinjected animals ( Figure S2 ). The number of cells that were immunoreactive for Phox2b was unaffected by DβH SAP treatment, suggesting that only C1 cells were affected. Furthermore, the toxin did not affect the number of choline acetyltransferasepositive facial motor neurons or THpositive cells outside the C1 (eg, A2 and A5; Figure S2 ). These results demonstrate selective lesion of C1 neurons.
Two weeks after DβHSAP treatment, vagotomized and urethaneanesthetized C1lesioned animals with intact carotid sinus nerves (n=7) exhibit reduced sSNA (72±6% of control; P=0.032) but normal resting MAP (116±4 mm Hg versus Figure 5 . P2Y1 receptors are functionally expressed by CO 2 -insensitive rostral ventrolateral medulla (RVLM) neurons but not retrotrapezoid nucleus (RTN) chemoreceptor neurons. A, Trace of firing rate from a chemosensitive RTN neuron shows that increasing CO 2 from 5% to 15% increases firing rate by ≈3 Hz. After returning to 5% CO 2 , focal application (arrows) of the selective P2Y1 receptor agonist (MRS2365, 100 µmol/L) had no effect on firing rate. B, Trace of firing rate from a CO 2 -insensitive neuron in the RVLM shows a robust and repeatable firing rate response to MRS2365. A, Summary box plot shows that cells in the rostral ventrolateral medulla (RVLM) can be differentiated based on responsiveness to CO 2 (15%) and MRS2365 (100 µmol/L). Chemosensitive retrotrapezoid nucleus neurons were largely MRS2365 insensitive (white bar, n=22), whereas the majority of CO 2 -insensitive neurons are activated by MRS2365 (red bar, n=46). After recording, cells were filled with biocytin for later immunohistochemical characterization; C1 cells were identified based on strong tyrosine hydroxylase (TH) immunoreactivity and weak phox2b labeling. Triple immunolabeling shows that a biocytin-filled MRS2365-sensitive cell (B, green) is immunoreactive for TH (C, red) and weakly immunoreactive for phox2b (D, blue); the merged image is shown in E. We found that 9 of 18 MRS2365-sensitive cells tested were TH positive. Scale bar, 20 μm. Figure 7A -7C, 7H-7K). The respiratory responses of C1lesioned animals to MRS2365 were also decreased compared with control animals ( Figure 7A , 7H-7K), suggesting that C1 cells proj ect to RTN chemoreceptors possibly as a means of integrat ing sympathetic activity with respiratory drive. We found that C1lesioned animals showed attenuation in the SNA and MAP, but not in PNA amplitude or frequency, responses elic ited by cyanide ( Figure 7A, 7D-7G ), suggesting that C1 cells are key determinants of the sympathoexcitatory response to peripheral chemoreceptor activation. Although C1 cells also contribute to the peripheral chemoreceptor ventilatory reflex, 36 the cyanideinduced ventilatory responses were retained in C1lesioned animals suggesting compensation by other com ponents of the respiratory circuit (eg, chemosensitive RTN neurons).
Discussion
Purinergic signaling has been shown to contribute to cen tral and peripheral chemoreflex control of cardiorespiratory function. However, molecular determinants of purinergic modulation of autonomic function remain poorly defined, and potential contribution of purinergic signaling to reflex regulation of blood pressure and sympathetic tone remains unclear. Here, we show that purinergic signaling at the level of the RVLM contributes to peripheral chemoreceptor regula tion of breathing, sympathetic outflow, and blood pressure by a P2Y1 receptor-dependent mechanism. We show that P2Y1 Figure 7 . Depletion of C1 neurons decreased pressor and sympathoexcitatory responses to activation of peripheral chemoreceptors and decreased cardiorespiratory responses to activation of P2Y1 receptors in the rostral ventrolateral medulla (RVLM). We made bilateral RVLM injections of anti-dopamine-β-hydroxylase (DβH)-SAP (4.2 ng/100 nL) to selectively lesion C1 cells (see Figure S1) . A, Traces of arterial pressure (AP), raw and integrated (∫) splanchnic sympathetic nerve activity (sSNA), and integrated phrenic nerve activity (∫PNA) show the response of a urethane-anaesthetized sham rat (left) and C1 lesion rat (right) to activation of peripheral chemoreceptors with cyanide (KCN: 40 μg/0.1 mL IV) and unilateral RVLM injection of MRS2365 (100 µmol/L, 50 nL). B, Representative photomicrograph shows that MRS2365 was injected into the RVLM at the level of the RTN. C, Plot of MRS2365 injection sites (Bregma −11.6 and −11.8). 34 Scale bar, 1 mm. Summary data (n=7 rats/group) show mean AP (MAP; D), sSNA (E), PNA amplitude (F), and PNA frequency (G) responses of sham and C1-lesioned animals to activation of peripheral chemoreceptors. Note that C1-lesioned animals exhibit reduced pressor and sympathoexcitatory responses but otherwise normal respiratory response to peripheral chemoreceptor activation. Summary data (n=7 rats/group) show MAP (H), sSNA (I), PNA amplitude (J), and PNA frequency (K) responses of sham and C1-lesioned animals to unilateral RVLM injection of MRS2365. These results confirm that P2Y1 receptors expressed on C1 cells are required for peripheral chemoreflex in the RVLM. *P<0.05. VII indicates facial motor nucleus; py, pyramidal tract; RPa, raphe pallidus; and Sp5, spinal tract of trigeminal nerve.
by guest on April 19, 2017 http://hyper.ahajournals.org/ Downloaded from receptors are preferentially expressed on C1 cells, but not che mosensitive neurons, and C1lesioned animals do not respond to RVLM injections of a P2Y1 agonist. In addition, in vivo inhibition of P2Y1 receptor signaling in the RVLM decreased peripheral chemoreceptor-mediated activation of breathing, SNA, and blood pressure, but did not change baroreflex con trol of sympathetic outflow or cardiorespiratory responses to RVLM injections of glutamate. We also found that pharma cological blockade of P2Y1 receptors in the RVLM caused a modest decrease in the somatosympathetic reflex. These results suggest that pharmacological blockade of P2Y1 does not alter excitability of C1 cells in a nonspecific manner and that P2Y1 receptors contribute to excitatory (glutamatergic) reflex control of C1 cells and sympathetic outflow. Consistent with this possibility, we show that inhibition of both P2Y1 receptors and glutamate receptors virtually abolished car diorespiratory responses to peripheral chemoreceptor activa tion, suggesting that purinergic nucleotides are coreleased with glutamate in the RVLM by peripheral chemoreceptor inputs. In addition, our anatomic evidence shows that ≈60% of NTS terminals in the RVLM are immunoreactive for both VGLUT2 and VNUT. This finding is consistent with evidence that ATP is coreleased with glutamate at certain central syn apses, 32 and together these results suggest that peripheral che moreceptor drive is relayed through the RVLM, in part, by a P2Y1dependent mechanism. Considering that overactivation of peripheral chemoreceptor drive, as occurs during obstruc tive sleep apnea (OSA), is associated with increased SNA and hypertension, 2, 3, 42 we propose that P2Y1 receptors could rep resent a therapeutic target for the treatment of OSAinduced hypertension.
P2Y1 Receptors Regulate the Peripheral Chemoreflex at the Level of the RVLM
It is well established that bulbospinal presympathetic neu rons located in the RVLM (ie, C1 and nonC1 cells) are critical determinants of reflex control of the cardiovascu lar system. 14, 43 Present and previous 15 evidence shows that targeted destruction of C1 cells virtually eliminated the sympathoexcitatory response to peripheral chemoreceptor activation in anesthetized rats. Furthermore, selective acti vation of C1 cells by channelrhodopsin2 has been shown to increase breathing, sympathetic activity, and blood pres sure, [44] [45] [46] whereas inhibition of C1 cells by activation of the allostatin receptor did the opposite. 47 However, despite the critical role of C1 cells in regulation of cardiorespiratory function, the identity of neurotransmitters and downstream effectors responsible for peripheral chemoreflex control of autonomic function at the level of the ventrolateral medulla remains incomplete.
Our results indicate that peripheral chemoreflex control of breathing, sympathetic activity, and blood pressure depends on both glutamate and purinergic signaling at the level of the RVLM. Specifically, we show in anesthetized rats that bilat eral injections of kynurenic acid significantly decreased the ventilatory, sympathetic, and pressor responses to peripheral chemoreceptor activation. These results are consistent with pre vious studies that used kynurenic acid 36 or APV ([2R]amino5 phosphonovaleric acid; specific Nmethyldaspartate receptor blocker) 48 to attenuate the response of RVLM presympathetic cells to peripheral chemoreceptor drive. In addition, we found that the majority of NTS terminals in the RVLM were immuno reactive for VGLUT2 (77%). Although we do not know whether VGLUT2positive NTS neurons that innervate the RVLM actu ally mediate the chemoreflex or contact C1 cells, these results are consistent with previous evidence 9 and suggest that gluta mate contributes to peripheral chemoreflex in the RVLM.
We also discovered that purinergic signaling via P2Y1 receptors expressed on C1 cells contributes to peripheral chemoreceptor regulation of breathing and blood pressure. This finding builds on the possibility that ATP is a key trans mitter throughout the peripheral chemoreceptor circuit. For example, as part of the first step in peripheral chemotrans duction glomus cells-the chemosensory unit of the carotid bodies-release ATP to activate P2X2 and P2X3 receptors on sensory nerve endings, which then relays this excitatory drive to neurons in the cNTS. 22 In the cNTS, application of ATP in awake rats mimicked cardiorespiratory responses (ie, bradycardia, hypertension, and tachypnea) to peripheral che moreceptor activation. 49, 50 Also consistent with a role of puri nergic signaling in peripheral chemoreflex, cNTS injections of glutamate receptor antagonists did not block sympathetic or bradycardic components of the chemoreceptor reflex in awake rats 51 or in the working heartbrain stem prepara tion, 52 whereas simultaneous antagonism of glutamate and P2 receptors in this region reduced pressor and sympathetic responses to chemoreflex activation. 19 In addition, presym pathetic neurons in the RVLM are activated by exogenous application of ATP analogs, 26, 29, 30 and application of puri nergic agonists into this region increased sympathetic tone 29 and blood pressure 29, 30 in anesthetized rats. Furthermore, inhibition of P2X receptors within the more caudal RVLM (at the level of the Bötzinger complex) blunted the ventila tory, but not pressure response elicited by peripheral che moreceptor activation in conscious rats. 23 In light of our evidence that P2Y1 receptors expressed on C1 cell mediate the peripheral chemoreceptor pressure response, we propose that differential expression of P2 receptors throughout the ventrolateral medulla could allow for parallel processing of respiratory and cardiovascular components of the peripheral chemoreflex.
It is also possible that P2Y1 receptors regulate other excit atory reflexes at the level of the RVLM. For example, we show that pharmacological blockade of P2Y1 receptors in the RVLM caused a modest reduction in the somatosympa thetic reflex by reducing the SNA peak elicited by electric stimulation of the sciatic nerve in anesthetized rats. Previous evidence reported this reflex to be mediated largely by gluta mate at this level of the RVLM. 37 Our evidence suggests that purinergic signaling via P2Y1 receptors in the RVLM may also contribute to the increase in sympathetic outflow evoked by stimulation of somatic afferents. Conversely, the inhibitory baroreflex was not affected by RVLM application of a P2Y1 receptor antagonist. These results are consistent with previous evidence that P2Y1 receptor blockade in the RVLM did not affect basal cardiorespiratory parameters 31 and suggests that P2Y1 receptors preferentially regulate excitatory reflex con trol of C1 cells. P2Y1 receptors are best known for their role in paracrine signaling between astrocytes and neurons, 53 but there is some evidence that these receptors are present postsynaptically and contribute to synaptic transmission. [54] [55] [56] For example, P2Y1 receptors appear to be expressed postsynaptically in layer V pyramidal neurons, and activation of these receptors has been shown to decrease synaptic strength and plasticity, [54] [55] [56] in part, by inhibiting voltagesensitive Ca 2+ channels. 55 Our results are consistent with the possibility that P2Y1 recep tors are situated postsynaptically on C1 cells; however, con trary to the studies noted above, we find that activation of P2Y1 on C1 cells increased excitability by activating a yet to be identified inward conductance (voltageclamp data are not shown). It should be noted that P2Y1 receptors may also be expressed by other cells types in the RVLM, including astrocytes, and our evidence that MRS2365 responsiveness was retained in synaptic block media does not rule out a potential indirect contribution of astrocytes to the peripheral chemoreflex.
Physiological Significance
OSA is defined as the occurrence of repetitive episodes of upper airway obstruction during sleep. OSA is a major health problem affecting ≤20% of adults in the United States and is considered a major risk factor for cardiovascular disease 3, 4, 57, 58 (eg, heart failure, stroke, hypertension, and coronary heart disease). The link between OSA and cardio vascular disease is thought to result from repeated apneic/ hypoxicmediated activation of the sympathetic nervous sys tem via peripheral chemoreceptors, which leads to hyperten sion and other cardiovascular problems. 57 Previous evidence showed that C1 cells are key determinants of the sympa thoexcitatory response to peripheral chemoreceptor activa tion. 15 In addition, an animal model of OSA showed that chronic intermittent hypoxia increased sympathoexcitatory responsiveness to RVLM injections of ATP, 28 suggesting that purinergic signaling in this region contributes to OSA induced activation of sympathetic activity and hypertension. Here, we show that purinergic signaling contributes to the peripheral chemoreflex at the level of the RVLM by a P2Y1 receptor-dependent mechanism. Therefore, P2Y1 receptors in the RVLM may represent new avenues for the treatment of hypertension resulting from overactivation of peripheral chemoreceptors.
Perspectives
Catecholaminergic C1 cells in the RVLM are key determinants of the sympathoexcitatory response to peripheral chemore ceptor activation. Overactivation of this reflex is thought to contribute to increased sympathetic activity and hypertension; however, molecular mechanisms linking peripheral chemore ceptor drive to hypertension remain poorly understood. Here, we show that P2Y1 receptors are preferentially expressed on C1 cells but not on chemoreceptor neurons, and C1lesioned animals do not respond to injections of a P2Y1 agonist in the ventrolateral medulla. In addition, inhibition of P2Y1 recep tor signaling in the ventrolateral medulla decreased peripheral chemoreceptormediated activation of breathing, sympathetic outflow, and blood pressure, as well as the somatosympathetic reflex, but did not change the baroreflex activation. Furthermore, inhibition of both P2Y1 receptors and glutamate receptors virtually abolished cardiorespiratory responses to peripheral chemoreceptor activation, suggesting that puriner gic nucleotides are coreleased with glutamate in the RVLM by peripheral chemoreceptor inputs. Our results incorporate the alreadyestablished notion that RVLM/C1 neurons are excited by peripheral chemoreceptors via a direct glutamatergic input from cNTS. 9 To this notion, we have added the concept that purinergic signaling also contributes to peripheral chemore flex control of autonomic function at the level of the RVLM/ C1 neurons via a P2Y1dependent mechanism. What Is New?
Sources of Funding
• We show for the first time that (1) purinergic signaling via P2Y1 receptors regulates peripheral chemoreceptor control of breathing, sympathetic nerve activity, and blood pressure; (2) activation of P2Y1 receptors in the rostral ventrolateral medulla mimics effects of peripheral chemoreceptor activation in control animals, but not in C1-lesioned animals; and (3) P2Y1 receptors are preferentially expressed on blood pressure-regulating C1 cells but not in respiratory chemoreceptor neurons.
What Is Relevant?
• Overactivation of the peripheral chemoreflex by repeated bouts of hypoxia is thought to contribute to hypertension and cardiovascular mortality associated with obstructive sleep apnea. Our evidence that P2Y1 receptors are differentially expressed by blood pressure-regulating cells and function as key determinants of peripheral chemoreceptor regulation of blood pressure identifies P2Y1 receptors as potential therapeutic targets for the treatment of hypertension associated with conditions, such as obstructive sleep apnea. We expect that our findings will be of great interest to a broad audience in the basic, clinical, and pharmaceutical community.
Summary Catecholaminergic C1 cells in the rostral ventrolateral medulla are key determinants of the sympathoexcitatory response to peripheral chemoreceptor activation. Overactivation of this reflex is thought to contribute to increased sympathetic activity and hypertension; however, molecular mechanisms linking peripheral chemoreceptor drive to hypertension remain poorly understood. Here, we use a combination of immunohistochemistry and in vivo and in vitro electrophysiological approaches to show that P2Y1 receptors are differentially expressed by C1 cells and function as important determinants of peripheral chemoreceptor regulation of breathing, sympathetic outflow, and blood pressure. These results suggest that P2Y1 receptors expressed on C1 cells represent a therapeutic target for the treatment of hypertension resulting from overactivation of peripheral chemoreceptors.
sites. The rats received bilateral injections (100 nl) placed symmetrically in the RVLM at the level of the C1, i.e., 100-200 μm below the lower edge of the field and 1.8 mm lateral to the midline and 100-200 μm caudal to the caudal end of the facial field. Animals were maintained for 2 weeks before they were used in physiological experiments. Consistent with previous evidence4, the toxin produced no obvious phenotype under resting conditions. The dose of anti DβH-SAP used in the present study (4.2 ng/100 nl) was selected based on previous experiments investigating the effects of injecting anti DβH-SAP into the C1 and A5 region 3, 4 . In addition, we did not observe any obvious gliosis or any other readily observable cytological difference between control and anti DβH-SAP rats (data not shown).
In vivo recordings of physiological variables
As previously described [1] [2] [3] 5 , mean arterial pressure (MAP), phrenic nerve activity (PNA), sSNA and end-expiratory CO 2 (etCO 2 ) were digitized with a micro1401 (Cambridge Electronic Design), stored on a computer, and processed off-line with version 6 of Spike 2 software (Cambridge Electronic Design, Cambridge, UK). Integrated phrenic nerve activity (∫PNA) and integrated splanchnic nerve activity (∫SNA) were obtained after rectification and smoothing (τ = 0.015 and 2s, respectively) of the original signal, which was acquired with a 30-300 Hz bandpass filter. ∫SNA was normalized within animals by assigning a value of 100 to resting SNA and a value of 0 to the minimum value recorded either during administration of a dose of phenylephrine that saturated the baroreflex (5 µg/kg, i.v.) or after ganglionic blockade (hexamethonium; 30 mg/kg, i.v.). Nerve activity was rectified and averaged over 1-s intervals and stored on hard disk for subsequent analysis. Noise was subtracted from the recordings prior to performing any calculations of evoked changes in SNA. A direct physiological comparison of the absolute level of nerve activity across nerves is not possible because of nonphysiological factors (e.g., nerve electrode contact, size of nerve bundle) and the ambiguity in interpreting how a given increase in voltage in one nerve relates to an increase in voltage in another nerve. Thus, all nerve activities were defined to be at their baseline physiological state just prior to their activation. These activities were normalized to 100%, and percent change was used to compare the magnitude of increase or decrease across nerves from these physiological baselines. PNA amplitude (PNA amp) and PNA frequency (PNA freq) were normalized in each experiment by assigning to each of the two variables a value of 100 at saturation of the chemoreflex (high CO 2 ) and a value of 0 to periods of apnea.
Potassium cyanide was used (KCN, 40 µg/0.1 ml, i.v.) to activate peripheral chemoreceptors because in vivo responses to KCN are robust, reversible, and blocked by carotid denervation 6 .
Tracer injections
Tracer injections were made while the rats were anaesthetized with a mixture of ketamine (80 mg kg -1 ) and xylazine (5mg kg -1 ) administered i.p. Surgery used standard aseptic methods, and after surgery, the rats were treated with the antibiotic ampicillin (100 mg kg -1 ) and the analgesic ketorolac (0.6 mg kg −1 , s.c.). A group of four rats received pressure injections of the anterograde tracer biotinylated dextran amine (BDA-lysine fixable, MW 10000; 10% w/v in 10 mm phosphate buffer, pH 7.4; Molecular Probes) into the commissural part of the nucleus of the solitary tract (cNTS) (25 μm tip diameter glass pipettes). These injections were made 0.4 mm caudal to the calamus scriptorius, in the midline and 0.3-0.5mm below the dorsal surface of the brainstem. These rats were allowed to survive 7-10 days following which they were
